Author:
Farley Daniel C,McCloskey Laura,Thorne Barbara A,Tareen Semih U,Nicolai Christopher J,Campbell David J,Bannister Richard,Stewart Hannah J,Pearson Laura JE,Moyer Bentley J,Robbins Scott H,Zielinski Leah,Kim Tae,Radcliffe Pippa A,Mitrophanous Kyriacos A,Gombotz Wayne R,Miskin James E,Kelley-Clarke Brenna
Subject
Genetics,Molecular Biology,Molecular Medicine
Reference33 articles.
1. FDA (2010), Briefing Document—Testing for replication competent retrovirus (RCR)/lentivirus (RCL) in retroviral and lentiviral vector based gene therapy products—Revisiting current FDA recommendations, U.S. Food and Drug Administration, pp 1-18
2. A third-generation lentivirus vector with a conditional packaging system;Dull;J Virol,1998
3. Design of a novel integration-deficient lentivector technology that incorporates genetic and posttranslational elements to target human dendritic cells;Tareen;Mol Ther,2014
4. FDA (2006), Guidance for Industry—Supplemental guidance on testing for replication competent retrovirus in retroviral vector based gene therapy products and during follow-up of patients in clinical trials using retroviral vectors, U.S. Food and Drug Administration, pp 1-13
5. Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapy;Odegard;J Immunother,2015
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献